Literature DB >> 17917970

Induction of multiple myeloma-specific cytotoxic T lymphocyte stimulation by dendritic cell pulsing with purified and optimized myeloma cell lysates.

Je-Jung Lee1, Bo-Hwa Choi, Hyun-Kyu Kang, Myong-Suk Park, Jung-Sun Park, Sang-Ki Kim, Thanh-Nhan Nguyen Pham, Duck Cho, Jong-Hee Nam, Young-Jin Kim, Joon-Haeng Rhee, Deok-Hwan Yang, Yeo-Kyeoung Kim, Hyeoung-Joon Kim, Ik-Joo Chung.   

Abstract

We investigated the possibility of immunotherapy for multiple myeloma (MM) using myeloma-specific cytotoxic T lymphocytes (CTLs) that were stimulated in vitro by dendritic cells (DCs) pulsing with purified and optimized myeloma lysates. CD14(+) cells were cultured in the presence of GM-CSF and IL-4. On day 6, the immature DCs were pulsed with the purified myeloma cell lysates, and then maturation of the DCs was induced by the addition of a cytokine cocktail. There were no differences in the phenotypic expressions of mature DCs that were generated by pulsing with CD138(+) cell lysates or total cell lysates. In optimization of the concentration of myeloma lysates, DCs pulsed with 10 microg/mL of myeloma lysate had greater allogeneic T-cell stimulatory capacities than those pulsed with higher concentrations of myeloma lysates. The CTL lines generated by DCs pulsed with myeloma lysates demonstrated potent cytotoxic activities against autologous target cells, but not against HLA-A2(-) cell lines or K562 cell lines. The DCs pulsed with myeloma lysates demonstrated a higher stimulatory capacity for autologous CTL compared with mature nonpulsed DCs. These results suggested that the DCs pulsed with purified and optimized myeloma cell lysates could generate potent myeloma-specific CTLs for approaches in MM.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17917970     DOI: 10.1080/10428190701583975

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  17 in total

1.  Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma.

Authors:  J Bae; T Hideshima; G L Zhang; J Zhou; D B Keskin; N C Munshi; K C Anderson
Journal:  Leukemia       Date:  2017-11-01       Impact factor: 11.528

2.  Immune oppression array elucidating immune escape and survival mechanisms in uveal melanoma.

Authors:  Fang Hou; Qi-Ming Huang; Dan-Ning Hu; Jost B Jonas; Wen-Bin Wei
Journal:  Int J Ophthalmol       Date:  2016-12-18       Impact factor: 1.779

3.  Feasibility of dendritic cell-based vaccine against glioblastoma by using cytoplasmic transduction peptide (CTP)-fused protein antigens combined with anti-PD1.

Authors:  Young-Hee Kim; Thi-Anh-Thuy Tran; Thi-Hoang-Oanh Duong; Shin Jung; In-Young Kim; Kyung-Sub Moon; Woo-Youl Jang; Hyun-Ju Lee; Je-Jung Lee; Tae-Young Jung
Journal:  Hum Vaccin Immunother       Date:  2020-05-13       Impact factor: 3.452

Review 4.  Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party.

Authors:  Jae Hoon Lee; Dong Soon Lee; Je Jung Lee; Yoon Hwan Chang; Jong Youl Jin; Deog-Yeon Jo; Soo Mee Bang; Hyo Jung Kim; Jin Seok Kim; Kihyun Kim; Hyeon Seok Eom; Chang Ki Min; Sung Soo Yoon; Sun Hee Kim; Cheolwon Suh; Kyung Sam Cho
Journal:  Int J Hematol       Date:  2010-06-11       Impact factor: 2.490

5.  Optimal culture conditions for the generation of natural killer cell-induced dendritic cells for cancer immunotherapy.

Authors:  Thanh-Nhan Nguyen-Pham; Deok-Hwan Yang; Truc-Anh Thi Nguyen; Mi-Seon Lim; Cheol Yi Hong; Mi-Hyun Kim; Hyun Ju Lee; Youn-Kyung Lee; Duck Cho; Soo-Young Bae; Jae-Sook Ahn; Yeo-Kyeoung Kim; Ik-Joo Chung; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Cell Mol Immunol       Date:  2011-08-08       Impact factor: 11.530

6.  Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders.

Authors:  Jooeun Bae; Yu-Tzu Tai; Kenneth C Anderson; Nikhil C Munshi
Journal:  Br J Haematol       Date:  2011-09-09       Impact factor: 6.998

Review 7.  Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies.

Authors:  Rebecca Karp Leaf; Hearn Jay Cho; David Avigan
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

8.  Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma.

Authors:  Amorette Barber; Tong Zhang; Christina J Megli; Jillian Wu; Kenneth R Meehan; Charles L Sentman
Journal:  Exp Hematol       Date:  2008-07-02       Impact factor: 3.084

9.  Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma.

Authors:  J Bae; R Carrasco; A-H Lee; R Prabhala; Y-T Tai; K C Anderson; N C Munshi
Journal:  Leukemia       Date:  2011-06-10       Impact factor: 11.528

Review 10.  Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions.

Authors:  Ivetta Danylesko; Katia Beider; Avichai Shimoni; Arnon Nagler
Journal:  Clin Dev Immunol       Date:  2012-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.